De-Risk Nucleic Acid Therapeutic Development With Strategic Outsourcing And Specialized Expertise

By Andrea Hawe, Chief Scientific Officer, and Anna Gebhardt, Business Development Manager

Following the rapid clinical validation and regulatory success of COVID-19 mRNA vaccines, nucleic acid therapeutics (NATs) are experiencing widespread momentum across the pharma industry. Known for their ability to treat infectious diseases, cancer, and genetic disorders, developers are exploring their potential to offer innovative treatment mechanisms to patients. However, to successfully bring these therapies to market, development teams need specialized formulation and development knowledge to navigate instability, lyophilized formulations, and scaleup challenges.

Though there are a number of potential development pitfalls with NATs, opting to work with an expert development partner allows companies to secure access to advanced analytic capabilities, delivery system expertise, and experienced scientific teams that can reduce timelines with strategic formulation development. Download the full article to learn more about how to mitigate the risks of NAT development with a partner and build a pathway to commercial success.